New Clinical Trial Led by Mass General Brigham Finds Solriamfetol Safely and Effectively Combats Severe Fatigue in Early Morning Shift Workers

The modern global economy runs continuously, propelled by millions of individuals who wake up and report to work long before the sun rises or long after it has set. While much of the scientific discourse surrounding shift work sleep disruptions has historically focused on overnight schedules—such as traditional graveyard shifts—a new clinical trial illuminates an equally pervasive yet largely ignored demographic: early morning shift workers. Spearheaded by researchers at Mass General Brigham, a landmark study published in NEJM Evidence demonstrates that the wake-promoting pharmaceutical drug solriamfetol, commercially known as Sunosi, significantly enhances alertness, cognitive function, and workplace performance in individuals who begin their days in the dead of night or the early hours of dawn.

This pivotal clinical trial addresses a glaring blind spot in sleep medicine. Despite early morning shifts representing the most common non-standard work schedule in the industrialized world, clinical interventions tailored specifically to this population have been virtually nonexistent until now. By rigorously testing solriamfetol in a controlled four-week trial, researchers have provided a much-needed pharmacological tool for a workforce that has long endured severe chronic fatigue with little institutional support.

Understanding the Hidden Burden of Early Morning Schedules

To fully grasp the significance of the Mass General Brigham study, one must examine the complex physiology of human sleep architecture. Approximately one in four workers in the modern workforce operates outside the standard 9-to-5 paradigm. Within this substantial cohort, millions of people begin their workdays between 3:00 a.m. and 7:00 a.m. Because many of these individuals do not work through the entire night, they frequently fail to identify as traditional "shift workers." Instead, they conceptualize their routines as simply starting the day earlier than the general population.

This semantic distinction, however, offers no protection against the immutable laws of human circadian biology. The human brain operates on an internal master clock regulated by the suprachiasmatic nucleus in the hypothalamus, which promotes sleepiness during the dark hours of the night by driving the secretion of melatonin and lowering core body temperature. When an individual wakes up at 4:00 a.m., they are violently forcing consciousness upon a brain that is biologically programmed to remain in deep slumber.

Consequently, early morning workers face a punishing biological double burden. First, they experience extreme, debilitating sleepiness during the early hours of their shifts, when cognitive demands are often high. Second, because their circadian rhythms are misaligned with their work demands, they frequently suffer from fragmented, poor-quality sleep when they finally attempt to rest during daylight hours. This chronic sleep debt precipitates a condition known as shift work disorder (SWD), characterized by persistent, excessive daytime sleepiness and chronic insomnia directly related to work schedules.

The Broader Health, Safety, and Economic Implications

The consequences of shift work disorder extend far beyond mere tiredness. Chronic circadian misalignment and sleep deprivation are associated with a myriad of severe adverse outcomes, including diminished mental sharpness, compromised executive functioning, impaired concentration, and reduced overall productivity. More alarmingly, the profound cognitive deficits induced by SWD present tangible public safety hazards. Sleep-deprived workers face a significantly elevated risk of motor vehicle accidents during their commutes home, as well as a higher incidence of costly or fatal workplace injuries due to delayed reaction times and impaired judgment.

Over the long term, epidemiological data links chronic shift work and associated sleep disorders to systemic health complications. These include cardiovascular diseases, metabolic syndrome, type 2 diabetes, obesity, and mental health challenges such as anxiety and depression. Despite these well-documented risks, therapeutic options have remained historically limited. While wake-promoting agents such as modafinil have been prescribed off-label or approved for shift work disorder, their efficacy has primarily been studied in overnight workers. Furthermore, these older medications often possess long half-lives that can interfere negatively with subsequent sleep periods, creating a frustrating cycle of pharmacological dependence and persistent sleep disruption.

Enter solriamfetol. Initially approved by the U.S. Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness in patients suffering from obstructive sleep apnea (OSA) and narcolepsy, solriamfetol acts as a dopamine-norepinephrine reuptake inhibitor (DNRI). Researchers hypothesized that its unique pharmacological profile—promoting sustained wakefulness over extended periods without severely disrupting subsequent rest cycles—made it an ideal candidate for mitigating the unique sleep-wake challenges faced by early morning employees.

Methodology and Chronology of the Clinical Trial

To test this hypothesis, a dedicated research team at Mass General Brigham designed a rigorous, randomized, double-blind, placebo-controlled clinical trial. The study enrolled 78 participants who were formally diagnosed with shift work disorder associated with early morning work schedules.

The chronology of the trial followed a structured protocol over a four-week intervention period. Following initial screenings and baseline assessments, participants were randomly assigned to receive either daily doses of solriamfetol or an inactive placebo on their respective workdays.

To evaluate the drug’s effectiveness under standardized, objective conditions, researchers utilized specialized testing environments. Participants were assessed in controlled, low-stimulation settings during hours that exactly mirrored their typical early morning work schedules. Throughout these simulated work shifts, researchers measured the participants’ physiological ability to maintain wakefulness. In addition to these objective metrics, the trial incorporated subjective evaluations. Participants and their evaluating clinicians regularly reported on daily functioning, perceived alertness, work performance, and the general management of routine daily tasks.

Key Findings and Clinical Significance

The results of the four-week trial exceeded expectations, offering clear evidence of the drug’s clinical utility. Participants who were administered solriamfetol demonstrated marked improvements in objective alertness metrics compared to those in the placebo group. During simulated work hours that coincided with their biological night, solriamfetol-treated participants were able to remain awake significantly longer and exhibited drastically reduced levels of severe sleepiness.

Furthermore, the qualitative data mirrored the objective findings. Both the participants themselves and their attending clinicians reported noticeable enhancements in overall functional capacity, improved professional performance, and a heightened ability to navigate daily responsibilities without the debilitating cloud of chronic exhaustion.

The principal investigators underscored that these improvements are not merely statistical artifacts, but represent profound, real-world enhancements in quality of life. Maintaining wakefulness and high cognitive acuity across a full eight-hour shift directly translates to fewer industrial errors, safer roadways, and a dramatic reduction in the occupational risks traditionally borne by early morning labor forces.

Expert Reactions and the Societal Contract of Essential Labor

The implications of the trial have drawn widespread attention within the medical community, prompting reflection on how society values and protects its essential workers.

"Until now, no clinical trial had tested a treatment for shift work disorder in early-morning shift workers, even though this is the most common type of shift schedule," stated senior author Dr. Charles A. Czeisler, PhD, MD, chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. "This study addresses a major gap by focusing on the workers who start their day when most people are still asleep."

Dr. Czeisler emphasized the fundamental disconnect between societal reliance on early-rising labor and the biological toll exacted upon those workers. "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost," he noted. "This study shows we can do better for them."

Echoing these sentiments, Dr. Kirsi-Marja Zitting, PhD, an investigator within the same division and first author of the study, highlighted the sheer physiological willpower required by this demographic. "People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep. That makes staying alert extraordinarily difficult, even when they are highly motivated," Dr. Zitting explained. "They are often dealing with a double burden—excessive sleepiness during work hours and difficulty sleeping enough when they have the chance to rest."

The realization that pharmacological interventions can safely alleviate this burden marks a paradigm shift in how occupational medicine addresses circadian misalignment. Rather than telling workers to simply adjust their sleep hygiene—advice that often proves futile against entrenched circadian biology—clinicians may soon have a targeted, evidence-based pharmacological option to support them.

Limitations and Future Directions in Sleep Medicine

Despite the promising outcomes of the Mass General Brigham trial, the research team has exercised appropriate scientific caution regarding the scope and limitations of their findings. The current study was explicitly designed as a four-week investigation involving a cohort of otherwise healthy adult participants. Consequently, while the short-term safety and efficacy profiles are robust, additional research is required to evaluate the long-term impacts, safety, and physiological consequences of chronic, extended solriamfetol use in this specific population.

Recognizing these horizons, the research group is not resting on its laurels. The team has already initiated preparations for the next phase of clinical investigation. Recruitment is currently underway for a follow-up clinical trial that will expand the scope of research by examining the efficacy of solriamfetol in overnight shift workers—those individuals who work straight through the dark hours from evening until morning. Data derived from this ongoing research will be crucial in supporting broader regulatory applications and label expansions for solriamfetol as a primary treatment for shift work disorder across all non-standard schedules.

The clinical trial was supported by funding and resources from pharmaceutical companies Jazz Pharmaceuticals and Axsome Therapeutics, alongside the Brigham and Women’s Hospital Center for Clinical Investigation, and is formally registered under clinical trial identifier NCT04788953. The study team also featured contributions from institutional researchers Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, Jeanne F. Duffy, and external collaborator Eileen B. Leary.

Ultimately, as the modern global economy continues to demand round-the-clock productivity, innovations in sleep medicine like those pioneered at Mass General Brigham offer a vital bridge between human biology and occupational necessity. By validating the struggles of early morning workers and providing a scientifically validated path toward improved alertness and safety, this research heralds a new era of proactive care for the millions of individuals who power the world while the rest of humanity sleeps.